Variceal bleeding: Pharmacological treatment and prophylactic strategies

Drugs

Volumn 68, Issue 16, 2008, Pages 2303-2324

  Villanueva, Cándid ^a,b   Balanzó, Joaquim ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Beta adrenergic receptor antagonists, therapeutic use; Gastrointestinal haemorrhage, treatment; Isosorbide mononitrate, therapeutic use; Octreotide, therapeutic use; Terlipressin, therapeutic use; Variceal haemorrhage, treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; IRBESARTAN; ISOSORBIDE MONONITRATE; LOSARTAN; NADOLOL; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; OCTREOTIDE; PRAZOSIN; PROPRANOLOL; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TERLIPRESSIN; TIMOLOL; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ASCITES; BLEEDING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HEPATIC VEIN; HUMAN; HYPERTENSION; INFECTION; INFECTION PREVENTION; INTESTINE ISCHEMIA; MONOTHERAPY; MORTALITY; PATHOPHYSIOLOGY; PATIENT SAFETY; PORTAL HYPERTENSION; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCLEROTHERAPY; STOMACH VARICES; SURVIVAL RATE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VARIX BLEEDING; VEIN LIGATION; VENOUS PRESSURE;

EID: 55049093452     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868160-00004     Document Type: Review

References (121)

1. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003; 98: 653-9
2. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-9
3. D'Amico G, De Franchis R, for the Cooperative Study group. Upper digestive bleeding in cirrhosis: post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612
4. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31
5. De Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001; 5: 645-63
6. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61
7. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505
8. North Italian Endoscopic Club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988; 319: 983-9
9. Polio J, Groszmann RJ. Hemodinamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986; 6: 318-31
10. Wiest R, Gorszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91
11. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397-410
12. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38: S54-68
13. Groszmann RJ. Hyperdynamic state in chronic liver diseases. J Hepatol 1993; 17 Suppl. 2: S38-40
14. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gardient predicts clinical descompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-8
15. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401-7
16. Feu F, García-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9
17. Boyer TD. Pharmacologic treatment of portal hypertension: past, present and future. Hepatology 2001; 34: 834-9
18. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48
19. Bosch J, Bordas JM, Mastai R, et al. Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology 1988; 8: 861-5
20. Nevens F, Van Steenbergen W, Yap SH, et al. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996; 38: 129-34
21. Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the hemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-7
22. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002; 35: 1305-12
23. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001; 120: 975-83
24. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995; 22: 106-11
25. Villanueva C, Ortiz J, Miñana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-7
26. Villanueva C, Planella M, Aracil C, et al. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonreponders to the usual somatostatin dose. Am J Gastroenterol 2005; 100: 624-30
27. Hillon P, Lebrec D, Muñoz C, et al. Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528-31
28. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5: 97-101
29. Escorsell A, Ferayoni L, Bosch J, et al. The portal pressure response to β-blockers is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112: 2012-6
30. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey. The case for nonselective β-blockers. Gastroenterology 2007; 133: 2029-36
31. Albillos A. Therapeutic tools in portal hypertension: drugs. In: Groszmann RJ, Bosch J, editors. Portal hypertension in the 21st century. Dordrecht: Kluwer Academic Publishers, 2004: 175-84
32. Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997; 113: 1794-7
33. Garcia-Tsao G, Sanyal A, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38
34. Groszmann RJ, Kravetz D, Bosch J, et al. Nitroglycerin improves the hemodynamic response to vasopresin in portal hypertension. Hepatology 1982; 2: 757-62
35. Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal pressure. Hepatology 1986; 6: 101-6
36. Garcia-Pagán JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. a randomized controlled study. Ann Intern Med 1991; 114: 869-73
37. Albillos A, García-Pagán JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115: 116-23
38. Vorobioff J, Picabea E, Gamen M, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993; 18: 477-84
39. García-Pagán JC, Morillas R, Bañares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003; 37: 1260-6
40. Morillas R, Planas R, Cabré E, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994; 20: 1502-8
41. Merkel C, Gatta A, Donada C, et al. Long-term effects of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995; 22: 808-13
42. Merkel C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology 1997; 26: 34-9
43. Bañares R, Moitinho E, Piqueras B, et al. Carvedilol a new beta-blocker with intrinsic anti-α1-adrenergic activity, has a greater portal hypotensiveb effect than propranolol in patients with cirrhosis. Hepatoloy 1999; 30: 79-83
44. Stanley A, Therapondos G, Helmy A, et al. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30: 479-84
45. Tripathi D, Therapondos G, Lui HF, et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16: 373-80
46. Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatoloy 2002; 36: 1367-73
47. Aracil C, López-Balaguer JM, Perez-Rabasco E, et al. Hemodynamic monitoring and rescue of nonresponders to first-line drug therapy with the combination of beta-blockers and prazosin or with ligation to prevent variceal rebleeding [abstract]. Hepatology 2005; 42 Suppl. 1: 399
48. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-24
49. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8
50. Villanueva C, López-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40: 757-65
51. Bosch J, García-Pagán JC. Revention of variceal rebleeding. Lancet 2003; 361: 952-4
52. Aracil C, Monfort D, Piqueras M, et al. Influence of spontaneous hemodynamic response on the efficacy of endoscopic therapy to prevent variceasl rebleeding [abstract]. J Hepatol 2005; 42 Suppl. 2: 76
53. Villanueva C, Balanzó J, Novella M, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624-9
54. Thalheimer U, Mela M, Patch D, et al. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004; 39: 286-90
55. Aracil C, Colomo A, Ordas I, et al. Acute hemodynamic response to beta-blockers for the prediction of long-term outcome in primary prophylaxis of variceal bleeding: final results of a prospective study [abstract]. J Hepatol 2007; 46 Suppl. 1: S35
56. Villanueva C, Aracil C, Balanzó J. What to do with non-responders? In: Groszmann RJ, Bosch J, editors. Portal hypertension in the 21st century. Dordrecht: Kluwer Academic Publishers, 2004: 337-48
57. Bureau C, Péron JM, Alric L, et al. 'A la carte' treatment of portal hypertension: adapting therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361-6
58. Gonzalez A, Agustin S, Perez M, et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 2006; 44: 806-12
59. Boyer TD. Changing clinical practice with measurements of portal pressure. Hepatology 2004; 39: 283-5
60. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280-2
61. Burroughs AK, Patch D. Management of variceal hemorrhage in cirrhotic patients. Gut 2001; 48: 738-40
62. De Franchis R. Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76
63. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61
64. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39: 746-53
65. Soriano G, Guarner C, Tomás A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267-72
66. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049-56
67. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinatre to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8
68. Calés P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001; 334: 23-8
69. Feu F, Ruiz del Arbol L, Bañares R, et al. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996; 111: 1291-9
70. Corley DA, Cello JP, Adkinsson W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001; 120: 946-54
71. D'Amico G, Pietrosi G, Tarantino I, et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277-91
72. Villanueva C, Ortiz J, Sàbat M, et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology 1999; 30: 384-9
73. De Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 439-55
74. Laine L, Cook D. Endoscopic ligation compared with sclerothepary for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995; 123: 280-7
75. Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25: 1101-4
76. Jensen DM, Kovacs TOG, Randall G, et al. Emergency sclerotherapy vs rubber band ligation for actively bleeding esophageal varices in a randomized prospective study [abstract]. Gastrointest Endosc 1994; 40: 241
77. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endioscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006; 45: 560-7
78. Bañares R, Albillos A, Rincón D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-15
79. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999; 19: 457-73
80. Moitinho E, Planas R, Bañares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712-8
81. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793-801
82. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30
83. Karsan HA, Morton SC, Shekelle PG, et al. Combination endoscopic band ligation and sclerotherapy compared with endoscopic band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: a meta-analysis. Dig Dis Sci 2005; 50: 399-406
84. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31: 1239-45
85. Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol plus isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55
86. Patch D, Sabin CA, Goulis J, et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 1013-9
87. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal bleeding. Gastroenterology 2002; 123: 728-34
88. El-Tahawy M, Mahmoud S, Waked I, et al. Band ligation versus medical therapy in prevention of variceal rebleeding: a randomized controlled study in schistosomal hepatic fibrosis and HCV coinfection [abstract]. Gastroenterology 2003; 124: A663-4
89. Sarin SK, Wadhawan M, Gupta R, et al. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci 2005 Aug; 50 (8): 1538-47
90. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 2006 Aug 15; 24 (4): 601-11
91. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 461-565
92. De la Peña J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-8
93. Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: combining endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008; 149: 109-22
94. García-Pagán JC, Villanueva C, Albillos A, et al. Nadolol + isosorbide-5-mononitrate (NAD + ISMN) vs NAD + ISMN + endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis: preliminary results of a multicenter RCT [abstract]. J Hepatol 2006; 44 Suppl. 2: S11-2
95. Jha SK, Kumar A, Sharma BC, et al. Endoscopic variceal ligation (EVL) plus propranolol (P) and isosorbide mononitrate (ISMN) versus EVL alone in secondary prophylaxis of variceal bleeding: a prospective RCT [abstract]. Hepatology 2007; 46 Suppl. 1: 250-1A
96. Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 1999; 30: 612-22
97. Escorsell A, Bañares R, García-Pagán JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35: 385-92
98. Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130: 1643-51
99. Lebrec D, Nouel O, Corbic M, et al. Propranolol: a medical treatment for portal hypertension? Lancet 1980; II: 180-2
100. Poynard T, Calès P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an anlysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991; 324: 1532-8
101. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33: 802-7
102. Khuroo MS, Khuroo NS, Farahat KL, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21: 347-61
103. Albillos A. Preventing first variceal hemorrhage in cirrhosis. J Clin Gastroenterol 2007; 41: S305-11
104. Sarin SK, Wadhawan M, Agarwal SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005; 100: 797-804
105. Tripathi D, Ferguson JW, Kochar N, et al. Multicenter randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed [abstract]. Hepatology 2007; 46 Suppl. 1: 269A
106. García-Pagán JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers. Gastroenterology 2001; 121: 908-14
107. Turnes J, Garcia-Pagan JC, Abraldes JG, et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006; 101: 506-12
108. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476-84
109. Angelico M, Carli L, Piat C, et al. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113: 1632-9
110. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003; 37: 359-65
111. Sarin SK. Gastric varices. In: Groszmann RJ, Bosch J, editors. Portal hypertension in the 21st century. Dordrecht: Kluwer Academic Publishers, 2004: 277-300
112. Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001; 33: 1060-4
113. Bernard-Chabert B, Sauerbruch T, Lo GH, et al. Prevention of rebleeding. In: De Franchi SR, editor. Portal hypertension IV: proceedings of the fourth Baveno international consensus workshop on methodology of diagnosis and treatment. Oxford: Blackwell, 2006: 262-84
114. Primignani M, Carpinelli L, Preatoni P, et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. Gastroenterology 2000; 119: 181-7
115. Payen JL, Cales P, Voigt JJ, et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995; 108: 138-44
116. Perez-Ayuso RM, Pique JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991; 337: 1431-4
117. Potamiano S, Carter CR, Anderson JR. Endoscopic laser treatment of diffuse gastric antral vascular ectasia. Gut 1994; 35: 461-3
118. González-Suárez B, Monfort D, Piqueras M, et al. Endoscopic treatment with argon plasma coagulation for portal hypertensive gastropathy with no response to pharmacological therapy [abstract]. J Hepatol 2003; 38 (185A): 59
119. Shneider BL. Approaches to the management of pediatric portal hypertension: results of an informal survey. In: Groszmann RJ, Bosch J, editors. Portal hypertension in the 21st century. Dordrecht: Kluwer Academic Publishers, 2004: 167-72
120. Anand BS. Drug treatment of the complications of cirrhosis in the older adult. Drugs Aging 2001; 18: 575-85
121. Ali Raza J, Movahed A. Use of cardiovascular medications in the elderly. Int J Cardiol 2002; 85: 203-15